Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.23821
Abstract: Key Points Question Are cerebrospinal fluid (CSF) neurofilament heavy (cNfH) levels associated with clinical progression in patients with Parkinson disease? Findings In this cohort study of 404 patients with Parkinson disease, higher baseline cNfH levels… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.32133
Abstract: Key Points Question What is the efficacy of acupuncture in treating patients who have Parkinson disease and anxiety? Findings In this randomized clinical trial including 64 patients with Parkinson disease and anxiety who underwent 8… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51028
Abstract: The brittle response (BR) in patients with Parkinson’s disease (PD) refers to a special type of levodopa‐induced dyskinesia (LID). This study aimed to describe the clinical characteristics of BR patients and to analyze the associated… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Brain and Behavior"
DOI: 10.1002/brb3.1880
Abstract: Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Brain and Behavior"
DOI: 10.1002/brb3.2690
Abstract: To synthesize recent empirical evidence for the prevention and management of falls and fear of falling in patients with Parkinson's disease (PD). read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1039
Abstract: Mevidalen (LY3154207) is a positive allosteric modulator of the dopamine D1 receptor that enhances the affinity of dopamine for the D1 receptor. The safety, tolerability, motor effects, and pharmacokinetics of mevidalen were studied in patients… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1147
Abstract: A randomized thorough QT study was conducted to assess the effects of apomorphine sublingual film (SL‐APO) on corrected QT interval (QTc) and other cardiac conduction parameters in patients with Parkinson's disease (PD) and “OFF” episodes.… read more here.
Sign Up to like & get recommendations! 2
Published in 2017 at "European Journal of Pain"
DOI: 10.1002/ejp.942
Abstract: Cannabis can alleviate pain of various etiologies. This study assessed the effect of cannabis on motor symptoms and pain parameters in patients with Parkinson's disease (PD). read more here.
Sign Up to like & get recommendations! 0
Published in 2023 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.13727
Abstract: The coronavirus disease 2019 (COVID‐19) pandemic has heavily impacted medical care of patients with Parkinson's disease (PwP). read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Archives of Orthopaedic and Trauma Surgery"
DOI: 10.1007/s00402-018-2899-8
Abstract: IntroductionThe aim of this study is to evaluate the difference in perioperative complication rate in total hip, bipolar hemiarthroplasties and total knee arthroplasty in patients with Parkinson disease in trauma and elective surgery in our… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Journal of Neural Transmission"
DOI: 10.1007/s00702-019-02016-w
Abstract: Fluctuating body weight is a commonly reported nonmotor feature in patients with Parkinson’s disease (PD). We hypothesised that striatal dopamine transporter (DAT) density at the time of diagnosis might play an important role in weight… read more here.